Vaxcyte PCVX 深 沪
等待开盘 03-26 09:30:00 美东时间
55.74
+1.070
+1.96%
华盛通- 最 高57.65
- 今 开55.54
- 成交量 111.30万股
- 最 低 55.3451
- 昨 收 54.67
- 总市值 80.22亿
- 52周最高 65.00
- 市盈率 静 --
- 换手率 0.77%
- 52周最低 27.66
- 委 比 98.64%
- 总股本 1.44亿
- 历史最高 121.055
- 量 比 0.85
- 振 幅 4.22%
- 历史最低 15.51
- 每 手 1
- 风险率 10.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vera Therapeutics appoints Jane Wright-Mitchell chief legal officer
Vera Therapeutics appoints Jane Wright-Mitchell chief legal officer Vera Therapeutics appointed Jane Wright-Mitchell as Chief Legal Officer, effective immediately. Wright-Mitchell previously served as a fractional general counsel supporting public and private life sciences companies. Her prior roles
03-25 19:30
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
Vera Therapeutics appoints Jane Wright-Mitchell, Pharm.D., J.D., as Chief Legal Officer, leveraging her over 25 years of experience in legal and compliance matters within the life sciences industry. Her expertise will support Vera’s upcoming commercial launch of atacicept, a dual BAFF/APRIL inhibitor for IgA nephropathy, and strengthen the company’s legal framework. Wright-Mitchell previously served as General Counsel at Vaxcyte, Inc. and brings ...
03-25 11:30
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
Vaxcyte Inc. announced positive results from a Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, in adults aged 50 and older. The study demonstrated robust opsonophagocytic activity and immunoglobulin G immune responses across all 31 serotypes, with a safety profile similar to PCV20. VAX-31 achieved non-inferiority criteria for 20 serotypes common with PCV20 and superiority for 11 unique serotypes. The high-dose VAX...
03-18 23:34
美股大行评级 | 最高300美元！大摩、小摩、花旗纷纷上调英伟达目标价；赛富时、C3.ai、Snowflake、Trade Desk等遭数十家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从47美元升至49美元；Citizens：维持Ironwood医药"跑赢大市"评级，目标价从8美元升至10美元
02-27 11:07
BTIG Maintains Buy on Vaxcyte, Raises Price Target to $89
BTIG analyst Thomas Shrader maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $85 to $89.
02-26 19:20
U.S. RESEARCH ROUNDUP-Chevron, GoDaddy, HP
U.S. RESEARCH ROUNDUP-Chevron, GoDaddy, HP Feb 25 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Chevron, GoDaddy and HP, on Wednesday. HIGHLIGHTS * Chevron Corp CVX.N : Gerdes Energy Research raises target price by $4
02-25 15:20
财报速睇 | Vaxcyte 2025财年年度营收0.00亿美元，同比增长0.0%；归母净利润亏损7.67亿美元，同比亏损扩大65.3%
华盛资讯2月25日讯，Vaxcyte公布2025财年年度业绩，公司年度营收0.00亿美元，同比增长0.0%，归母净利润亏损7.67亿美元，同比亏损扩大65.3%。
02-25 12:08
财报速睇 | Vaxcyte 2025财年Q4营收0.00亿美元，同比增长0.0%；归母净利润亏损2.47亿美元，同比亏损扩大79.8%
华盛资讯2月25日讯，Vaxcyte公布2025财年Q4业绩，公司Q4营收0.00亿美元，同比增长0.0%，归母净利润亏损2.47亿美元，同比亏损扩大79.8%。
02-25 06:14
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Vaxcyte announces fourth quarter and full year 2025 financial results with $2.4 billion in cash, cash equivalents and investments. The company advanced its VAX-31 Phase 3 adult clinical program, with OPUS-1, OPUS-2, and OPUS-3 trials underway. Enrollment in the VAX-31 infant Phase 2 dose-finding study was completed, and manufacturing capabilities were enhanced to support commercialization. VAX-A1, targeting Group A Strep, is set to begin Phase 1 ...
02-24 21:05
